edoc

In vitro; and; in vivo; antischistosomal activity profiling and pharmacokinetics of ozonide carboxylic acids

Biendl, S. and Häberli, C. and Chen, G. and Wang, W. and Zhong, L. and Saunders, J. and Pham, T. and Wang, X. and Wu, J. and Charman, S. A. and Vennerstrom, J. L. and Keiser, J.. (2023) In vitro; and; in vivo; antischistosomal activity profiling and pharmacokinetics of ozonide carboxylic acids. ACS Infect Dis, 9 (3). pp. 643-652.

Full text not available from this repository.

Official URL: https://edoc.unibas.ch/94516/

Downloads: Statistics Overview

Abstract

Praziquantel, the only drug in clinical use for the treatment and control of schistosomiasis, is inactive against developing infections. Ozonides are synthetic peroxide derivatives inspired by the naturally occurring artemisinin and show particularly promising activity against juvenile schistosomes. We conducted an in-depth characterization of the in vitro and in vivo antischistosomal activity and pharmacokinetics of lead ozonide carboxylic acid OZ418 and four of its active analogs. In vitro, the ozonides featured rapid and consistent activity against schistosomula and adult schistosomes at double-digit micromolar EC(50) values. Potency did not vary considerably between Schistosoma spp. The zwitterionic OZ740 and OZ772 were more active in vivo compared to their non-amphoteric carboxylic acids OZ418 and OZ748, despite their much lower systemic plasma exposure (AUC). The most active compound in vivo was ethyl ester OZ780, which was rapidly transformed to its parent zwitterion OZ740 and achieved ED(50) values of 35 +/- 2.4 and 29 +/- 2.4 mg/kg against adult and juvenile Schistosoma mansoni, respectively. Ozonide carboxylic acids represent promising candidates for further optimization and development due to their good efficacy against both life stages together with their broad activity range against all relevant parasite species.
Faculties and Departments:09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH)
09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH) > Department of Medical Parasitology and Infection Biology (MPI) > Helminth Drug Development (Keiser)
UniBasel Contributors:Häberli, Cécile and Keiser, Jennifer
Item Type:Article, refereed
Article Subtype:Research Article
ISSN:2373-8227 (Electronic)2373-8227 (Linking)
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:09 May 2023 06:10
Deposited On:09 May 2023 06:10

Repository Staff Only: item control page